29 January 2025
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
Grant of Options and
Warrants
Ondine Biomedical Inc.
(AIM: OBI), a
Canadian life sciences company developing light-activated
antimicrobial treatments, announces the issuance of options and
warrants as detailed below.
Grant of Options
On 28 January 2025, Ondine granted a
total of 500,000 options to subscribe for new common shares in the
Company ("Options") to its Non-executive Directors as
follows:
|
Director
|
Position
|
Options
granted
|
Exercise
price
|
Total options now
held
|
|
Jean Charest
|
Non-executive Chair
|
200,000
|
12
pence
|
340,000
|
|
Jean Duvall
|
Non-executive Director
|
75,000
|
12
pence
|
150,000
|
|
Mike Farrar
|
Non-executive Director
|
75,000
|
12
pence
|
250,000
|
|
Junaid Bajwa
|
Non-executive Director
|
75,000
|
12
pence
|
150,000
|
|
Margaret Shaw
|
Non-executive Director
|
75,000
|
12
pence
|
75,000
|
The Options all have an exercise
price of 12 pence,
being the closing share price on 28
January 2025 (the "Approval Date"), the day on
which the grant of Options was approved by the Board. The Options
vest evenly over a period of four
years, with 25% vesting on each of the four
successive anniversaries of the Approval Date and can be exercised
for a period of five years from the Approval Date.
Following the grant of the Options,
the Company has 13,105,000
options to subscribe for new common shares
outstanding, which represents 3.24%
per cent of the Company's current issued share
capital.
The FCA notifications in respect of
the above Option grants, made in accordance with the requirements
of the UK Market Abuse Regulation, are appended below.
Issue of Warrants
The Company's Board has authorised
the issuing of warrants to certain key vendors. A total of
1,450,000 warrants are to be issued, entitling the holders to
acquire common shares of the Company at a strike price of
17 pence each. The
warrants have an expiration date of 31
December 2025.
A total of 250,000 Warrants are to
be issued to Livingstone Life Sciences
Limited, a wholly-owned company by former Ondine Board Member and current
Chief Medical Officer, Dr. Simon Sinclair, who is leading Ondine's
Phase 3 clinical trial. The Warrants vest
immediately upon grant and have an expiration date of 31 December
2025.
Enquiries:
|
Ondine Biomedical
Inc.
|
www.ondinebio.com
|
|
Carolyn Cross, CEO
|
Via Vane
Percy & Roberts
|
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
|
Phil Davies, Sam Butcher
|
+44 (0)20
7496 3000
|
|
|
|
|
RBC
Capital Markets (Broker)
|
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20
7653 4000
|
|
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77
1000 5910
|
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian
life sciences company and leader in light-activated antimicrobial
therapies (also known as 'photodisinfection'). Ondine has a
pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of
development.
Ondine's nasal photodisinfection
system has a CE mark in Europe and is approved in Canada and
several other countries under the name Steriwave®. In
the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical
indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
1. Jean
Charest
2. Jean
Duvall
3. Mike
Farrar
4. Junaid
Bajwa
5. Margaret Shaw
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
1.
Non-executive Chair (PDMR)
2.
Non-executive Director (PDMR)
3.
Non-executive Director (PDMR)
4.
Non-executive Director (PDMR)
5.
Non-executive Director (PDMR)
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Ondine Biomedical Inc.
|
|
b)
|
LEI
|
213800QO681575J97813
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Options to subscribe for Common
Shares
|
|
Identification code
|
ISIN: CA68234M2058
|
|
b)
|
Nature of the transaction
|
Grant of options to subscribe for
common shares of no par value
|
|
c)
|
Price(s) and volume(s)
|
|
PDMR
|
Price(s)
|
Volume(s)
|
|
Jean Charest
|
Exercise price of
12 pence per
share
|
200,000
|
|
Jean Duvall
|
Exercise price of
12 pence per
share
|
75,000
|
|
Mike Farrar
|
Exercise price of
12 pence per
share
|
75,000
|
|
Junaid Bajwa
|
Exercise price of
12 pence per
share
|
75,000
|
|
Margaret Shaw
|
Exercise price of
12 pence per
share
|
75,000
|
|
|
d)
|
Aggregated information:
·Aggregated volume
·Price
|
N/A
|
|
e)
|
Date of the transaction
|
28 January
2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Simon Sinclair
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Former Non-executive Director
(PDMR)
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Ondine Biomedical Inc.
|
|
b)
|
LEI
|
213800QO681575J97813
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Warrants
|
|
Identification code
|
ISIN: CA68234M2058
|
|
b)
|
Nature of the transaction
|
Grant of options to subscribe for
common shares of no par value
|
|
c)
|
Price(s) and volume(s)
|
250,000 warrants at a price of 17
pence each
|
|
d)
|
Aggregated information:
·Aggregated volume
·Price
|
N/A
|
|
e)
|
Date of the transaction
|
28 January
2025
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
